Published in Cancer Weekly, April 10th, 2001
(alpha)-fetoprotein is expressed preferentially in hepatic cells. Gene therapy using the (alpha)-fetoprotein promoter exhibits tissue specificity; however, the promoter does not boast strong transcriptional activity.
To overcome this obstacle, Y. Sakai and colleagues created two recombinant adenoviral vectors: one with the cre gene under control of the (alpha)-fetoprotein promoter and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.